Polyclinique Vauban — Clinical Trial Site

26 Registered trials

6 Currently recruiting

Organisation

Polyclinique Vauban

Location

Valenciennes, France

Identifier

ORG-100044787

Address

10 Avenue Vauban, 59300, France

Departments

#3322:Cardiology
1511:Medical Oncology
2214: Cardiology
2304: Service Cardiologie
2417: Cardiology
3322, Cardiology
Cardiologie
Cardiology
Cardiology Service
Département de Cardiologie
NA
Service Cardiologie
Service de Cardiologie
Service de cardiologie - 3 éme étage
Service de soins continus Cardiologie/Néphrologie

Clinical trials at this site (26)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
SPironolactONe for the maintenance of Sinus Rhythm in hypertensive patients with atrial fibrillation and preserved left ventricular ejection… Pending

2024-518146-25-00 patients with atrial fibrillation and preserved left ve 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting

2024-519219-32-00 Heart Failure With Reduced Ejection Fraction 5 2025-06-23
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Heart failure with mildly reduced or preserved ejection 5 2024-03-27
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17